Dividends & Buybacks ·
Keros Therapeutics to receive $20 million development milestone payment from Takeda Pharmaceuticals
KROSKeros Therapeutics, Inc.
On September 29, 2026, Keros Therapeutics announced it will receive a $20 million development milestone payment from partner Takeda Pharmaceuticals following the dosing of the first patient in the ELRiSE MF Phase 3 clinical trial for elritercept. The company expects to distribute 25% of the net cash proceeds from this payment to its stockholders upon receipt. This milestone is part of a global license agreement effective January 16, 2025, which included a $200 million upfront payment and offers potential additional milestones exceeding $1.1 billion plus tiered royalties. Keros Therapeutics operates as a clinical-stage biopharmaceutical company focused on developing novel therapeutics for disorders linked to dysfunctional TGF-ß signaling.